Pasithea Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: KTTAW · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1841330
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Pasithea Therapeutics held a shareholder vote on June 26, 2024. Details TBD.
AI Summary
Pasithea Therapeutics Corp. filed an 8-K on June 26, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about the specific proposals voted on or the outcome of the vote.
Why It Matters
This filing indicates that Pasithea Therapeutics Corp. held a shareholder vote, which could impact corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any new financial information or significant operational changes.
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant
- June 26, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted for a vote by Pasithea Therapeutics Corp. security holders?
The filing does not specify the exact proposals voted on by security holders.
When was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 26, 2024.
What is the principal executive office address for Pasithea Therapeutics Corp.?
The principal executive offices are located at 1111 Lincoln Road, Suite 500, Miami Beach, FL 33139.
What is the telephone number for Pasithea Therapeutics Corp.?
The telephone number is (786) 977-3380.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-06-26 17:00:11
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share KTTA The Nasdaq Capital M
Filing Documents
- ea0208474-8k_pasithea.htm (8-K) — 42KB
- 0001213900-24-056205.txt ( ) — 257KB
- ktta-20240626.xsd (EX-101.SCH) — 4KB
- ktta-20240626_def.xml (EX-101.DEF) — 26KB
- ktta-20240626_lab.xml (EX-101.LAB) — 36KB
- ktta-20240626_pre.xml (EX-101.PRE) — 25KB
- ea0208474-8k_pasithea_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASITHEA THERAPEUTICS CORP. Dated: June 26, 2024 By: /s/ Tiago Reis Marques Name: Tiago Reis Marques Title: Chief Executive Officer 2